Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576836 · ClinicalTrials.gov registry record · Phase 2
Thymus Transplantation Dose in DiGeorge #932
A Phase 2 study of DiGeorge Syndrome and Complete DiGeorge Anomaly, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00576836 is a Phase 2 study of DiGeorge Syndrome and Complete DiGeorge Anomaly that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 7 participants, below the 451-participant average among 4 other DiGeorge Syndrome trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00576836, a Phase 2 study of DiGeorge Syndrome and Complete DiGeorge Anomaly, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
One purpose of this study is to determine whether the amount of cultured thymus tissue implanted into DiGeorge anomaly infants has any effect on the immune outcome. Another purpose of this study is to determine whether parental parathyroid transplantation (in addition to cultured thymus tissue implantation (CTTI) can help both the immune and the calcium problems in DiGeorge infants with hypocalcemia. \[Funding Source - FDA Office of Orphan Products Development (OOPD)\]
Conditions Studied
Interventions
- BIOLOGICAL Cultured Thymus Tissue Implantation (CTTI)
- OTHER Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-09-02 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00576836
The ClinicalTrials.gov registry entry for NCT00576836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 451-participant average among 4 other DiGeorge Syndrome trials with a reported enrollment target (98% lower). The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with DiGeorge Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Cultured Thymus Tissue Implantation (CTTI) is the first listed.
NCT00576836 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00576836 about?
NCT00576836 is a clinical study titled "Thymus Transplantation Dose in DiGeorge #932". One purpose of this study is to determine whether the amount of cultured thymus tissue implanted into DiGeorge anomaly infants has any effect on the immune outcome. Another purpose of this study is to determine whether parental parathyroid transplantation (in addition to cultured thymus tissue impla...
What is the current status of trial NCT00576836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2004-09-02. Estimated completion is 2019-12-31.
What conditions does trial NCT00576836 study?
This clinical trial studies the following conditions: DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, DiGeorge Anomaly.
What interventions are being tested in trial NCT00576836?
The interventions under investigation include: Cultured Thymus Tissue Implantation (CTTI) (BIOLOGICAL), Cultured Thymus Tissue Implantation with Parathyroid Transplantation (OTHER).
Who is sponsoring clinical trial NCT00576836?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00576836 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for DiGeorge Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
RECRUITING · Phase 2
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
RECRUITING
-
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.